Charter Oak Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Charter Oak Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-31	Closed	-$2K	–	254
2022 Q2	$2K	Hold	31	–	–	﹤0.01%	818
2022 Q1	$2K	Hold	31	–	–	﹤0.01%	859
2021 Q4	$2K	Hold	31	–	–	﹤0.01%	767
2021 Q3	$2K	Hold	31	–	–	﹤0.01%	744
2021 Q2	$2K	Hold	31	–	–	﹤0.01%	734
2021 Q1	$2K	Hold	31	–	–	﹤0.01%	701
2020 Q4	$2K	Buy	+31	New	+$2.46K	﹤0.01%	659

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charter Oak Capital Management's BMRN Position: Q3 2022 in Review

Charter Oak Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2022, closing a stake of 31 shares — an estimated $2K sold.

Charter Oak Capital Management first reported a position in BMRN in Q4 2020 and held it in 7 quarters. The position peaked at $2K in Q2 2022. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

Charter Oak Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Charter Oak Capital Management sold 31 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $2K.
Charter Oak Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 7 quarters.
Charter Oak Capital Management's BioMarin Pharmaceuticals position peaked at $2K in Q2 2022.
551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Charter Oak Capital Management's 13F filing for Q3 2022, filed 6 Dec 2022.